Literature DB >> 21807060

Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization.

F Javier Martínez-Lobo1, Francisco Díez-Fuertes, Isabel Simarro, José M Castro, Cinta Prieto.   

Abstract

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is highly heterogenic. This heterogeneity has an effect on antigenic composition of PRRSV and might create differences in sensitivity to neutralization between isolates. The sensitivity to neutralization could be an important feature of PRRSV isolates because it is likely that isolates resistant to neutralization pose a significant challenge for the development of vaccines that elicit broad protective immunity. Nonetheless, little information is available for understanding or categorizing the viral neutralization phenotype of PRRSV isolates. Consequently, the main purpose of this study was to determine whether PRRSV isolates differ in their susceptibility to neutralization and if they can be classified in different categories based on their neutralization phenotype. For this purpose, a panel of 39 PRRSV isolates and a set of 30 hyperimmune monospecific sera were used in cross-neutralization assays. The results of this study indicate that PRRSV isolates differ in their sensitivity to neutralization and k-means clustering system allowed classifying the isolates in four different categories according to their neutralization phenotype: highly sensitive, sensitive, moderately sensitive and resistant to neutralization. Further analyses using two additional clustering systems that considered individual data for the classification of the isolates confirmed that classification obtained by k-means is accurate in most cases and that only in a few instances classification is less stringent. Sequences of GP3, GP4 and GP5 were analyzed but no correlation could be found between the sequence of previously identified neutralizing epitopes or the number of N-linked glycosylation sites in different proteins and the neutralization phenotype of the isolates. These data provide the first systematic assessment of overall neutralization sensitivities of a panel of diverse PRRSV isolates. The classification of the isolates provides a useful tool to facilitate the systematic characterization of neutralizing antibody production elicited by new vaccine candidates.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807060     DOI: 10.1016/j.vaccine.2011.07.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.

Authors:  Sally R Robinson; Michael C Rahe; Diem K Gray; Kyra V Martins; Michael P Murtaugh
Journal:  Virus Res       Date:  2018-02-03       Impact factor: 3.303

2.  Indian porcine reproductive and respiratory syndrome virus bears discontinuous deletion of 30 amino acids in nonstructural protein 2.

Authors:  T K Rajkhowa; G Jagan Mohanarao; A Gogoi; L Hauhnar
Journal:  Virusdisease       Date:  2016-08-27

3.  Analysis of ORF5 and full-length genome sequences of porcine reproductive and respiratory syndrome virus isolates of genotypes 1 and 2 retrieved worldwide provides evidence that recombination is a common phenomenon and may produce mosaic isolates.

Authors:  G E Martín-Valls; L K Kvisgaard; M Tello; L Darwich; M Cortey; A J Burgara-Estrella; J Hernández; L E Larsen; E Mateu
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

4.  Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection.

Authors:  Ivan Díaz; Mariona Gimeno; Laila Darwich; Nuria Navarro; Liudmila Kuzemtseva; Sergio López; Ivan Galindo; Joaquim Segalés; Margarita Martín; Joan Pujols; Enric Mateu
Journal:  Vet Res       Date:  2012-04-19       Impact factor: 3.683

5.  Immune responses in pigs induced by recombinant DNA vaccine co-expressing swine IL-18 and membrane protein of porcine reproductive and respiratory syndrome virus.

Authors:  Xiaodong Zhang; Xiaoli Wang; Lianzhi Mu; Zhuang Ding
Journal:  Int J Mol Sci       Date:  2012-05-11       Impact factor: 6.208

6.  Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestation.

Authors:  Kiwon Han; Hwi Won Seo; Changhoon Park; Chanhee Chae
Journal:  Vet Res       Date:  2014-02-02       Impact factor: 3.683

7.  Isolation of Porcine Reproductive and Respiratory Syndrome Virus GP5-Specific, Neutralizing Monoclonal Antibodies From Hyperimmune Sows.

Authors:  Jordan E Young; Cheryl M T Dvorak; Simon P Graham; Michael P Murtaugh
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

8.  Immunogenic and protective properties of GP5 and M structural proteins of porcine reproductive and respiratory syndrome virus expressed from replicating but nondisseminating adenovectors.

Authors:  Elodie Roques; Aurélie Girard; Marie-Claude St-Louis; Bernard Massie; Carl A Gagnon; Martin Lessard; Denis Archambault
Journal:  Vet Res       Date:  2013-03-11       Impact factor: 3.683

9.  Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.

Authors:  Marc F Geldhof; Merijn Vanhee; Wander Van Breedam; Jan Van Doorsselaere; Uladzimir U Karniychuk; Hans J Nauwynck
Journal:  BMC Vet Res       Date:  2012-10-03       Impact factor: 2.741

10.  Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus.

Authors:  Jing-Qiang Ren; Wen-Chao Sun; Hui-Jun Lu; Shu-Bo Wen; Jie Jing; Fu-Long Yan; Hao Liu; Cun-Xia Liu; Peng-Peng Xiao; Xing Chen; Shou-Wen Du; Rui Du; Ning-Yi Jin
Journal:  BMC Vet Res       Date:  2014-06-10       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.